Gain Therapeutics, Inc. (GANX): Long-Term Debt
$401.0K
As of 2025-12-31
$343.7K
As of 2026-06-30
-12.7%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $401.0K | -8.6% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $438.5K | -22.8% | 2025-03-27, Balance as of period end |
| 2023-12-31 | $567.9K | -5.9% | 2024-03-26, Balance as of period end |
| 2022-12-31 | $603.4K | -13.1% | 2023-03-23, Balance as of period end |
| 2021-12-31 | $694.3K | n/a | 2022-03-25, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $401.0K | -8.6% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $27.13M | -6.3% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $0 | -100.0% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $2.12M | n/a |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $10.00M | n/a |
| Propanc Biopharma, Inc. (PPCB) | 2025-06-30 | $537.9K | +34.7% |
| Clene Inc. (CLNN) | 2025-12-31 | $17.79M | n/a |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $0 | n/a |
| Tempest Therapeutics, Inc. (TPST) | 2024-12-31 | $6.40M | -39.0% |
Compare GANX, EMMA, HCWB, MENS side by side · Screen every company in Pharmaceutical Preparations ↗